Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serelaxin in acute heart failure (phase IIIb, Slovakia)
2013-001498-25Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Heart Failure (AHF) comparing Serelaxin + standard therapy with Placebo + standard therapy (2 arms). Primary endpoint: Time to confirmed cardiovascular death. Started Aug 2013; status: completed.
02
Drugs
serelaxin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2013-001498-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001498-25.